Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Biomea Fusion reported full-year 2025 financial results highlighting advancement in clinical trials for icovamenib, a novel oral therapy for diabetes, and BMF-650 for obesity. The company initiated two Phase II trials for icovamenib with primary endpoint data expected in Q4 2026 and advanced its GLP-1 receptor agonist, BMF-650, into Phase I trials …